艾博韦泰联合多替拉韦在初治艾滋病患者中的疗效分析

Potential efficacy of combined use of albuvirtide and dolutegravir in newly diagnosed AIDS patients

目的分析艾博韦泰(ABT)联合多替拉韦(DTG)方案在初治艾滋病患者中的短期治疗后病毒载量及免疫功能变化,评估其疗效。方法收集2020年3月至2021年2月初治艾滋病患者186例,患者均接受ABT联合DTG治疗4周,观察患者体内病毒载量及免疫功能变化,并进行统计学分析。结果ABT联合DTG治疗4周后患者的血浆HIV RNA明显降低(t=32.87,P<0.001),部分患者低于检测下限(<40copies/ml);同时ABT联合DTG治疗4周后患者的免疫功能明显改善(P=0.001);并且无论基线HIV RNA水平高低,血清CD4^(+)T淋巴细胞水平(P<0.001)、CD4^(+)T/CD8^(+)T淋巴细胞比值明显增高(P=0.005);尤其是高病毒载量患者,免疫功能恢复更加明显。结论对于初治艾滋病患者,无论基线HIV RNA水平高低,使用ABT联合DTG抗病毒治疗方案可在短期内快速降低患者体内血浆HIV RNA水平,改善患者免疫功能,使患者明显获益,为初治艾滋病患者提供有价值的治疗方案。

Objective To analyze the short-term efficacy and immune function of albuvirtide and dolutegravir in newly treated patients with AIDS,and to assess its efficacy.Method 186 patients with AIDS were collected from March 2020 to February 2021.Patients received ABT combined with DTG for 4 weeks,then observed the the curative effect and immune level,and statistically analyzed.Result After 4 weeks of ABT+DTG combined treatment,the plasma HIV RNA of patients was significantly decreased(t=32.87,P<0.001),and some patients were lower than the detection limit(<40 copies/ml).At the same time,the immune function of patients was significantly improved after 4 weeks of ABT+DTG combination therapy(P=0.001).The results showed that regardless of the baseline HIV RNA level,the serum CD4^(+)T lymphocyte level(P<0.001)and CD4^(+)T/CD8^(+)T ratio were significantly increased(P=0.005).Immune function reconstruction is more obvious,especially in patients with high viral load.Conclusion For newly diagnosed AIDS patients,the ABT+DTG antiviral therapy can rapidly reduce HIV RNA levels and improve the immune function in the short term,regardless of the HIV viral load in the body.It can improve the immune function of patients,and make patients benefit significantly.It provide a valuable treatment plan for newly diagnosed AIDS patients.